The Masonic Cancer Center creates a collaborative research environment focused on the causes, prevention, detection, and treatment of cancer; applying that knowledge to improve quality of life for patients and survivors; and sharing its discoveries with other scientists, students, professionals, and the community.
Read the 2016 Annual Report
Chainbreaker was established with the objective to fund life-saving cancer research at the Masonic Cancer Center, University of Minnesota. Chainbreaker weekend is August 11-13, 2017. Read more and register.
12th Annual Cancer Survivorship Conference
A cancer diagnosis can alter the landscape of your life. Although it doesn't redefine you, it can change your lifetime healthcare needs. This conference. on May 6, 2017 at the McNamara Alumni Center, University of Minnesota, is focused on questions and issues survivors and their famikies often face after cancer treatment. Read more and register.
The Masonic Cancer Center's clinical partner is University of Minnesota Health. Visit mhealth.org/cancer to find information about cancer care, providers and cancer clinic locations.
Cancer Information Nurse Line
Reach a nurse specializing in cancer care, Monday through Friday from 8 a.m. to 4:30 p.m.
New cancer treatments must prove to be safe and effective in scientific studies with a certain number of patients before they can be made widely available. Through clinical trials, researchers learn which approaches are more effective than others.
Our Research Focus
The Masonic Cancer Center brings together scientists from different disciplines to discover processes that affect cancer. It is home to state-of-the-art research tools and some of the world's top cancer researchers in:
Drug developed at University of Minnesota increases survival in dogs with cancer; shows potential for use in humans
A breakthrough trial at the University of Minnesota testing a new UMN-developed drug resulted in improved survival rates for dogs diagnosed with a cancer called hemangiosarcoma (HSA).
Immune response to HPV impacts head and neck cancer prognosis
A new study in JAMA Oncology finds that antibodies to human papillomavirus detectable in blood serum are reliable indicators of five-year head and neck cancer survival.
Masonic Cancer Center, founded in 1991, is a National Cancer Institute Comprehensive Cancer Center, one of only 47 institutions in the United States and two in Minnesota to hold that designation.
A state-of-the-art facility with 52,000 square feet of laboratory space, which expands the opportunities for collaborative research at the Masonic Cancer Center. It's the gateway to the Biomedical Discovery District.